Nicoletta Biglia

Summary

Affiliation: Institute for Cancer Research and Treatment
Country: Italy

Publications

  1. ncbi request reprint Effects of surgical and adjuvant therapies for breast cancer on sexuality, cognitive functions, and body weight
    Nicoletta Biglia
    Department of Gynaecological Oncology, University of Turin, Mauriziano Umberto I Hospital and Institute for Cancer Research and Treatment of Candiolo IRCC, Turin, Italy
    J Sex Med 7:1891-900. 2010
  2. ncbi request reprint Mirtazapine for the treatment of hot flushes in breast cancer survivors: a prospective pilot trial
    Nicoletta Biglia
    Department of Gynaecological Oncology, University of Turin, Mauriziano Umberto I Hospital, Turin, Italy
    Breast J 13:490-5. 2007
  3. ncbi request reprint Hormonal replacement therapy after gynaecological cancer
    Nicoletta Biglia
    Institute for Cancer Research and Treatment IRCC, Academic Department of Gynaecological Oncology, University of Turin, Candiolo, Italy
    Gynakol Geburtshilfliche Rundsch 46:191-6. 2006
  4. ncbi request reprint Menopause after breast cancer: a survey on breast cancer survivors
    Nicoletta Biglia
    Academic Department of Gynecological Oncology, University of Turin, Mauriziano Umberto I degrees Hospital and Institute for Cancer Research and Treatment of Candiolo, Turin, Italy
    Maturitas 45:29-38. 2003
  5. ncbi request reprint Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment
    Nicoletta Biglia
    Academic Department of Gynaecological Oncology, Mauriziano Umberto I Hospital of Turin and Institute for Cancer Research and Treatment of Candiolo, University of Turin, Largo Turati 62, 10129 Turin, Italy
    Endocr Relat Cancer 14:549-67. 2007
  6. ncbi request reprint Modification of serum IGF-I, IGFBPs and SHBG levels by different HRT regimens
    Nicoletta Biglia
    Academic Department of Gynaecological Oncology, Institute for Cancer Research and Treatment of Candiolo, University of Turin, Mauriziano Umberto 1st Hospital, Turin, Italy
    Maturitas 45:283-91. 2003
  7. ncbi request reprint Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors
    N Biglia
    Academic Gynaecological Oncology Department, University of Turin, IRCC Institute for Cancer Research and Treatment of Candiolo, Turin and Mauriziano Umberto I Hospital, Largo Turati 62, Torino 10128, Italy
    Maturitas 52:78-85. 2005
  8. doi request reprint Extensive nodal disease may impair axillary reverse mapping in patients with breast cancer
    Riccardo Ponzone
    Gynecological Oncology, University of Turin, Institute for Cancer Research and Treatment of Candiolo, Turin, Italy
    J Clin Oncol 27:5547-51. 2009
  9. ncbi request reprint Comparison of two models for the prediction of nonsentinel node metastases in breast cancer
    Riccardo Ponzone
    Academic Division of Gynecological Oncology, Institute for Cancer Research and Treatment of Candiolo, Strada Provinciale 142, 10060 Candiolo, Turin, Italy
    Am J Surg 193:686-92. 2007
  10. ncbi request reprint Dynamic contrast-enhanced MRI and sonography in patients receiving primary chemotherapy for breast cancer
    Filippo Montemurro
    Unit of Medical Oncology, Institute for Cancer Research and Treatment IRCC, Strada Provinciale 142, Candiolo, Torino, Italy
    Eur Radiol 15:1224-33. 2005

Collaborators

Detail Information

Publications50

  1. ncbi request reprint Effects of surgical and adjuvant therapies for breast cancer on sexuality, cognitive functions, and body weight
    Nicoletta Biglia
    Department of Gynaecological Oncology, University of Turin, Mauriziano Umberto I Hospital and Institute for Cancer Research and Treatment of Candiolo IRCC, Turin, Italy
    J Sex Med 7:1891-900. 2010
    ..Abrupt estrogen deficiency following chemotherapy and/or hormonal therapy plays an important role in worsening of sexuality...
  2. ncbi request reprint Mirtazapine for the treatment of hot flushes in breast cancer survivors: a prospective pilot trial
    Nicoletta Biglia
    Department of Gynaecological Oncology, University of Turin, Mauriziano Umberto I Hospital, Turin, Italy
    Breast J 13:490-5. 2007
    ..The more frequent side effect was somnolence. A sizeable compiliance problem has been observed due to the reluctance to take antidepressant drugs and to side effects...
  3. ncbi request reprint Hormonal replacement therapy after gynaecological cancer
    Nicoletta Biglia
    Institute for Cancer Research and Treatment IRCC, Academic Department of Gynaecological Oncology, University of Turin, Candiolo, Italy
    Gynakol Geburtshilfliche Rundsch 46:191-6. 2006
    ..The use of HRT in breast cancer patients is, at present, considered contra-indicated, even if results of clinical trials are not concordant. Therapeutic non-hormonal alternatives may be proposed to these patients...
  4. ncbi request reprint Menopause after breast cancer: a survey on breast cancer survivors
    Nicoletta Biglia
    Academic Department of Gynecological Oncology, University of Turin, Mauriziano Umberto I degrees Hospital and Institute for Cancer Research and Treatment of Candiolo, Turin, Italy
    Maturitas 45:29-38. 2003
    ..Due to the younger age and the ever wider use of adjuvant chemotherapy and antiestrogens, menopausal symptoms are a frequent cause of concern for breast cancer patients...
  5. ncbi request reprint Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment
    Nicoletta Biglia
    Academic Department of Gynaecological Oncology, Mauriziano Umberto I Hospital of Turin and Institute for Cancer Research and Treatment of Candiolo, University of Turin, Largo Turati 62, 10129 Turin, Italy
    Endocr Relat Cancer 14:549-67. 2007
    ..In fact, metastases are more frequently distributed to the gastrointestinal tract, peritoneum/retroperitoneum and gynaecological organs than in IDC...
  6. ncbi request reprint Modification of serum IGF-I, IGFBPs and SHBG levels by different HRT regimens
    Nicoletta Biglia
    Academic Department of Gynaecological Oncology, Institute for Cancer Research and Treatment of Candiolo, University of Turin, Mauriziano Umberto 1st Hospital, Turin, Italy
    Maturitas 45:283-91. 2003
    ..During the menopause, levels of SHBG, IGF-I and IGFBPs are significantly modified by the use of different HRT regimens...
  7. ncbi request reprint Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors
    N Biglia
    Academic Gynaecological Oncology Department, University of Turin, IRCC Institute for Cancer Research and Treatment of Candiolo, Turin and Mauriziano Umberto I Hospital, Largo Turati 62, Torino 10128, Italy
    Maturitas 52:78-85. 2005
    ..To evaluate the efficacy and tolerability of long-term treatment with venlafaxine at low dose for the reduction of vasomotor symptoms in breast cancer survivors...
  8. doi request reprint Extensive nodal disease may impair axillary reverse mapping in patients with breast cancer
    Riccardo Ponzone
    Gynecological Oncology, University of Turin, Institute for Cancer Research and Treatment of Candiolo, Turin, Italy
    J Clin Oncol 27:5547-51. 2009
    ..The aim of axillary reverse mapping (ARM) is to preserve arm lymphatics in patients with breast cancer who underwent surgical axillary staging...
  9. ncbi request reprint Comparison of two models for the prediction of nonsentinel node metastases in breast cancer
    Riccardo Ponzone
    Academic Division of Gynecological Oncology, Institute for Cancer Research and Treatment of Candiolo, Strada Provinciale 142, 10060 Candiolo, Turin, Italy
    Am J Surg 193:686-92. 2007
    ..It is debated whether all patients with a positive sentinel node dissection (SLND) should be submitted to axillary lymph node dissection (ALND). Models have been developed to estimate the likelihood of nonsentinel node (non-SLN) metastases...
  10. ncbi request reprint Dynamic contrast-enhanced MRI and sonography in patients receiving primary chemotherapy for breast cancer
    Filippo Montemurro
    Unit of Medical Oncology, Institute for Cancer Research and Treatment IRCC, Strada Provinciale 142, Candiolo, Torino, Italy
    Eur Radiol 15:1224-33. 2005
    ....
  11. doi request reprint Identification of new genes associated with breast cancer progression by gene expression analysis of predefined sets of neoplastic tissues
    Daniela Cimino
    Institute for Cancer Research and Treatment, Unit of Gynecological Oncology, University of Turin Medical School, Candiolo, Turin, Italy
    Int J Cancer 123:1327-38. 2008
    ..This work provides a novel set of genes that could be used as independent prognostic markers and potential drug targets for breast cancer...
  12. ncbi request reprint Body mass index (BMI) and breast cancer: impact on tumor histopathologic features, cancer subtypes and recurrence rate in pre and postmenopausal women
    Nicoletta Biglia
    Gynaecological Oncology Department, University of Turin, Institute for Cancer Research and Treatment IRCC, Candiolo, Turin and Mauriziano Umberto I Hospital, Turin, Italy
    Gynecol Endocrinol 29:263-7. 2013
    ..Higher BMI was significantly associated with a shorter DR-FS in postmenopausal women but the independent prognostic role of obesity was not confirmed in our analysis...
  13. ncbi request reprint Personal use of hormone therapy by postmenopausal women doctors and male doctors' wives in Italy after the publication of WHI trial
    Nicoletta Biglia
    Gynaecological Oncology Department, University of Turin, Mauriziano Umberto I Hospital, Largo Turati 62, 10128 Turin, Italy
    Maturitas 54:181-92. 2006
    ..To describe the prevalence of hormone replacement therapy (HT) use by postmenopausal women doctors and doctors' wives in Italy and to explore the relationship between their personal characteristics and HT use...
  14. doi request reprint Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study
    Nicoletta Biglia
    Department of Oncological Gynaecology, University of Turin, Institute for Cancer Research and Treatment of Candiolo IRCC, Turin, Italy
    Gynecol Endocrinol 26:404-12. 2010
    ..The increase of serum estrogens levels during treatment with vaginal estrogen at these dosages is minimal...
  15. ncbi request reprint Personal use of HRT by postmenopausal women doctors and doctors' wives in the north of Italy
    Nicoletta Biglia
    Gynecological Oncology Department, University of Turin, Mauriziano Umberto I Hospital, Turin, Italy
    Gynecol Endocrinol 18:165-74. 2004
    ..This is in contrast with the very low prevalence of use in the general population and may lead, in the near future, to a larger use of HRT in Italy...
  16. doi request reprint Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients--data from LIBERATE trial
    Piero Sismondi
    Academic Department of Obstetrics and Gynaecology, University of Torino Medical School, Mauriziano Umberto I Hospital, Turin, Italy
    Maturitas 70:365-72. 2011
    ..Tibolone, a synthetic steroid, is effective in reducing these symptoms in healthy post-menopausal women, but this has never been studied in a large breast cancer population...
  17. ncbi request reprint Pathological classification of ductal carcinoma in situ of the breast correlates with surgical treatment and may be predicted by mammography
    Riccardo Ponzone
    Academic Division of Gynaecological Oncology, Institute for Cancer Research and Treatment IRCC of Candiolo, University of Turin, Azienda Sanitaria Ospedaliera Ordine Mauriziano, 10060 Candiolo, Turin, Italy
    Breast 16:495-502. 2007
    ..We suggest that pathological features of DCIS are associated with surgical outcome and may be predicted by mammography...
  18. ncbi request reprint Hormone replacement therapy in cancer survivors
    Nicoletta Biglia
    Academic Department of Gynaecological Oncology, Institute for Cancer Research and Treatment IRCC, University of Turin, Candiolo, Largo Turati 62, 10128 Torino, Italy
    Maturitas 48:333-46. 2004
    ..The purpose of this paper is to review biological and clinical evidences in favour and against HRT use in the different tumours and to propose an algorithm that can help choosing the treatment for the single woman...
  19. doi request reprint Clinical and radiological predictors of nipple-areola complex involvement in breast cancer patients
    Marta D'Alonzo
    Academic Division of Gynecological Oncology, University of Turin, A O Ordine Mauriziano, Largo Turati 62, 110128 Turin, Italy
    Eur J Cancer 48:2311-8. 2012
    ..Nipple-areola sparing mastectomy (NSM) is increasingly used in patients with non-locally advanced breast carcinoma. Literature data on the preoperative assessment of the nipple-areola complex (NAC) are inconsistent...
  20. ncbi request reprint Vaginal oestrogen therapy after breast cancer: is it safe?
    Riccardo Ponzone
    Academic Department of Gynaecological Oncology, University of Turin, Mauriziano Umberto I Hospital of Turin and Institute for Cancer Research and Treatment of Candiolo, Largo Turati 62, Turin 10129, Italy
    Eur J Cancer 41:2673-81. 2005
    ..Further research is warranted to confirm whether vaginal estrogens are safe in symptomatic breast cancer patients who are non-responsive to alternative treatments...
  21. ncbi request reprint Influence of estrogens and antiestrogens on the expression of selected hormone-responsive genes
    Piero Sismondi
    Cattedra di Ginecologia Oncologica, Istituto per la Ricerca e la Cura del Cancro, Universita degli Studi di Torino, Candiolo, Italy
    Maturitas 57:50-5. 2007
    ..Our results underline the complexity of genomic responses to estrogen in breast cancer cells and strongly suggest that the molecular characterization of estrogen agonists and antagonists used in human therapy should be carefully studied...
  22. ncbi request reprint Antihormones in prevention and treatment of breast cancer
    Riccardo Ponzone
    Academic Unit of Gynaecological Oncology, University of Turin, Institute for Cancer Research and Treatment IRCC of Candiolo and A S O Ordine Mauriziano, Turin, Italy
    Ann N Y Acad Sci 1089:143-58. 2006
    ..Furthermore, it is likely that treatment tailoring will be increased by the definition of patient subgroups that could derive larger benefits from AIs (progesterone receptor-negative, HER-2-overexpressing) or other new drugs...
  23. doi request reprint Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials
    Nicoletta Biglia
    Gynecological Oncology Department, University of Turin, Mauriziano Umberto I Hospital, Turin, Italy
    Gynecol Endocrinol 26:804-14. 2010
    ..To critically discuss the use of tibolone (T), in light of a series of very recent double-blind placebo (PL) controlled trials (LISA, LIFT, OPAL, THEBES, LIBERATE) conducted worldwide in a large number of postmenopausal women (PMW)...
  24. ncbi request reprint HRT and gynaecologic cancer after WHI: old stuff or new doubts?
    Piero Sismondi
    Academic Department of Gynaecological Oncology, Mauriziano Umberto I Hospital and Institute for Cancer Research and Treatment IRCC, University of Torino Medical School, Largo Turati 62, 10128 Torino, Italy
    Maturitas 48:13-8. 2004
    ....
  25. ncbi request reprint Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging
    Laura Martincich
    Department of Diagnostic Imaging, Institute for Cancer Research and Treatment, Candiolo, Torino, Italy
    Breast Cancer Res Treat 83:67-76. 2004
    ..We sought to investigate whether DCE-MRI could be used to predict histological response in patients undergoing primary chemotherapy (PCT) for breast cancer...
  26. ncbi request reprint Sentinel node dissection as definitive treatment for node negative breast cancer patients
    R Ponzone
    Academic Gynaecological Oncology Unit, Institute for Cancer Research and Treatment IRCC of Candiolo, Mauriziano Umberto I Hospital, Largo Turati 62, 10128 Turin, Italy
    Eur J Surg Oncol 29:703-6. 2003
    ..Negative sentinel node may predict tumour-free axillary nodes in breast cancer. We report the performance of sentinel node dissection at our Institution...
  27. ncbi request reprint How to manage the menopause following therapy for breast cancer. is raloxifene a safe alternative?
    P Sismondi
    Department of Gynecological Oncology, University of Turin, Mauriziano Umberto I Hospital, c so G Ferraris 122, 10128, Turin, Italy
    Eur J Cancer 36:S74-6. 2000
    ..For symptomatic patients, the association of raloxifene with different drugs which have demonstrated efficacy in the control of vasomotor symptoms is now under evaluation...
  28. ncbi request reprint Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer
    R Ponzone
    Academic Units of Gynaecological Oncology, University of Turin, Institute for Cancer Research and Treatment IRCC of Candiolo, A S O Ordine Mauriziano, Turin, Italy
    Ann Oncol 17:1631-6. 2006
    ....
  29. doi request reprint Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines
    Daniele Recupero
    Department of Biomedical Sciences and Human Oncology, University of Turin, Via Santena 7, Turin, Italy
    J Pathol 229:390-9. 2013
    ..Our data suggest that a reduction of the receptor steric hindrance as induced by enzymatic shedding may facilitate the binding capacity of trastuzumab...
  30. doi request reprint Clinical significance of microinvasion in borderline ovarian tumors and its impact on surgical management
    Annamaria Ferrero
    Academic Division of Gynecologic Oncology, Mauriziano Hospital, Turin, Italy
    Int J Gynecol Cancer 22:1158-62. 2012
    ..The aims of this study were to evaluate the rate of recurrences in borderline ovarian tumors (BOTs) with microinvasion and to evaluate the possibility to enlarge fertility-sparing surgery in this group of patients...
  31. ncbi request reprint The influence of hormone replacement therapy on the pathology of breast cancer
    N Biglia
    Gynaecological Oncology Unit, Institute for Cancer Research and Treatment IRCC of Candiolo and Mauriziano Umberto I Hospital, University of Turin, Largo Turati 62, 10128 Turin, Italy
    Eur J Surg Oncol 31:467-72. 2005
    ..To assess whether the pathological characteristics of breast carcinomas arising in post-menopausal women who ever used hormonal replacement therapy (HRT) differ from those of post-menopausal patients who never used HRT...
  32. ncbi request reprint Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer
    Carlo Campagnoli
    Unit of Endocrinological Gynecology, Ospedale Sant Anna di Torino, Turin, Italy
    Clin Breast Cancer 13:433-8. 2013
    ..We present the results of a new analysis of our study on the effect of metformin on the bioavailability of sex hormones...
  33. ncbi request reprint Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival
    Christian Sfiligoi
    Institute for Cancer Research and Treatment, Laboratory of Gynecological Oncology, Str Prov 142, 10060 Candiolo, Turin, Italy
    Int J Cancer 103:466-74. 2003
    ..In ZR75.1 and T47D cells, expression of ANG2 mRNA was increased up to 10-fold by treatment with estrogen within 24 hr. Although preliminary, these data suggest a possible role of ANG2 as a prognostic factor for primary breast cancer...
  34. ncbi request reprint Sentinel node biopsy for breast cancer: yes, less surgery is better surgery
    P Sismondi
    Academic Gynecological Oncology Unit, Institute for Cancer Research and Treatment IRCC of Candiolo, Turin, and Mauriziano Umberto 1st Hospital of Turin, Italy
    Eur J Gynaecol Oncol 24:107-12. 2003
    ..Many issues, some of which will be discussed in the light of our personal experience, still need to be tested in clinical controlled trials...
  35. doi request reprint Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E
    N Biglia
    Department of Gynecological Oncology, University of Turin, Mauriziano Umberto I Hospital and Institute for Cancer Research and Treatment of Candiolo IRCC, Turin, Italy
    Climacteric 12:310-8. 2009
    ..The secondary objective was to evaluate the effect of the treatments on the quality of sleep and other aspects of the quality of life...
  36. ncbi request reprint Treatment options for pregnant women with ovarian tumors
    Rosanna Mancari
    Medical Gynecologic Oncology Division, European Institute of Oncology, Milan, Italy Academic Division of Gynaecology and Obstetrics, Mauriziano Hospital Umberto I, University of Turin, Turin, Italy Fertility and Pregnancy Unit, Medical Gynecologic Oncology Division, European Institute of Oncology, Milan, Italy Breast Cancer Translational Research Laboratory J C Heuson, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium Preventive Gynecology Division and Pathology Division, European Institute of Oncology, Milan, Italy Academic Division of Gynaecology and Obstetrics, Mauriziano Hospital Umberto I, University of Turin, Turin, Italy and Medical Gynecologic Oncology Division, European Institute of Oncology, University of Milan Bicocca, Italy
    Int J Gynecol Cancer 24:967-72. 2014
    ..Preliminary data suggest that platinum salts and taxanes are safe during pregnancy. Management of ovarian tumors in pregnancy requires a multidisciplinary approach to guarantee an optimal treatment for the mother and the fetus. ..
  37. pmc Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids
    Nicoletta Biglia
    Department of Obstetrics and Gynaecology, Mauriziano Umberto I Hospital, University of Turin, Turin, Italy
    Drug Des Devel Ther 8:285-92. 2014
    ..On the grounds of this evidence, the administration of 5 mg/day ulipristal acetate for 3 months is suggested for different patient categories and allows for planning a treatment strategy tailored to meet an individual patient's needs. ..
  38. doi request reprint The cellular apoptosis susceptibility CAS/CSE1L gene protects ovarian cancer cells from death by suppressing RASSF1C
    Annalisa Lorenzato
    Department of Oncological Sciences, University of Torino School of Medicine, Turin, Italy
    FASEB J 26:2446-56. 2012
    ..Our data show that CAS/CSE1L protects ovarian cancer cells from death through transcriptional suppression of a proapoptotic gene and suggest that the localization of CAS/CSE1L dictates its function...
  39. ncbi request reprint Management of risk of breast carcinoma in postmenopausal women
    N Biglia
    Academic Department of Gynecological Oncology, Mauriziano Umberto I Hospital Torino and Institute for Cancer Research and Treatment I RCC of Candiolo, Turin, Italy
    Endocr Relat Cancer 11:69-83. 2004
    ..Chemoprevention with tamoxifen and with the new selective estrogen receptor modulators, namely raloxifene, is very promising and deserves a thorough discussion for all high-risk women...
  40. ncbi request reprint Quantitative real-time RT-PCR analysis of eight novel estrogen-regulated genes in breast cancer
    V Sorbello
    Laboratory of Oncological Gynecology, Institute for Cancer Research and Treatment, Candiolo, Turin, Italy
    Int J Biol Markers 18:123-9. 2003
    ....
  41. ncbi request reprint HRT, breast and endometrial cancers: strategies and intervention options
    P Sismondi
    Department of Gynaecological Oncology, University of Turin, Italy
    Maturitas 32:131-9. 1999
    ..It is equally important that the best strategies for breast and endometrial surveillance in women commencing HRT be outlined, bearing in mind that the diffusion of hormonal therapies may be halted by unnecessary medical interventions...
  42. ncbi request reprint Molecular characterization of breast cancer aggressiveness
    N Biglia
    Institute for Cancer Research and Treatment, University of Turin, Candiolo TO, Italy
    Int J Biol Markers 18:36-9. 2003
  43. ncbi request reprint Breast cancer and hormone replacement therapy: putting the risk into perspective
    C Campagnoli
    Endocrinological Gynecology Unit, St Anna Hospital, Turin, Italy
    Gynecol Endocrinol 15:53-60. 2001
    ..However, the theoretical possibility exists that low doses of oral estrogens, plus a progestin providing progesterone-like effects only, will be shown to be associated with a limited breast cancer risk increase...
  44. ncbi request reprint Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
    Riccardo Ponzone
    J Natl Cancer Inst 96:883-4; author reply 884-5. 2004
  45. ncbi request reprint The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer
    George M Yousef
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    Breast Cancer Res Treat 78:149-58. 2003
    ..Like other kallikreins, the KLK9 gene was found to be regulated by steroid hormones, mainly estrogens and progestins, in cancer cell lines...
  46. ncbi request reprint Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells
    Claudio Scafoglio
    Dipartimento di Patologia Generale, Seconda Universita degli Studi di Napoli, Vico L De Crecchio 7, 80138 Naples, Italy
    J Cell Biochem 98:1163-84. 2006
    ....
  47. ncbi request reprint Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer
    George M Yousef
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Ave, Toronto, Ontario, M5G 1X5 Canada
    Clin Chem 48:1241-50. 2002
    ..Like the genes that encode PSA and other kallikreins, the KLK5 gene was found to be regulated by steroid hormones in the BT-474 breast cancer cell line...
  48. ncbi request reprint A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome
    Luigi Cicatiello
    Dipartimento di Patologia Generale, Seconda Universita degli Studi di Napoli, Vico L De Crecchio 7, 80138 Napoli, Italy
    J Mol Endocrinol 32:719-75. 2004
    ....
  49. ncbi request reprint Breast cancer and sex steroids: critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer
    Angiolo Gadducci
    Department of Procreative Medicine, Division of Gynecology and Obstetrics, University of Pisa, Via Roma 56, 56127 Pisa, Italy
    Gynecol Endocrinol 20:343-60. 2005
    ..New administration routes and novel hormone regimens are currently under evaluation, and these new HRT modalities could have different impact on breast cancer risk because of their metabolic and pharmacodynamic effects...
  50. pmc Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion
    Maria Silvia Giretti
    Department of Reproductive Medicine and Child Development, University of Pisa, Pisa, Italy
    PLoS ONE 3:e2238. 2008
    ..We studied the effect of estrogen receptor recruitment on actin cytoskeleton remodeling and breast cancer cell movement and invasion. Moreover, we characterized the signaling steps through which these actions are enacted...